ToolGen Incorporated

Equities

A199800

KR7199800004

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 18:00:00 2024-05-22 EDT			5-day change	1st Jan Change
60,400 ^KRW	-1.79%		-5.18%	-13.96%

2023	ToolGen Incorporated announced that it has received KRW 33 billion in funding	CI
2023	ToolGen Incorporated announced that it expects to receive KRW 33 billion in funding	CI

ToolGen Incorporated announced that it expects to receive KRW 10.0223744 billion in funding

October 12, 2016

ToolGen Incorporated (XKON:A199800) announced a private placement of 391,499 common shares at a price 25,600 per share for gross proceeds of KRW 10,022,374,400 on October 13, 2016. The transaction has been approved by board of director of the company. The transaction is expected to closed October 14, 2016.

Latest news about ToolGen Incorporated

ToolGen Incorporated announced that it has received KRW 33 billion in funding	11-01	CI
ToolGen Incorporated announced that it expects to receive KRW 33 billion in funding	23-10-30	CI
Toolgen Leads Development of Numerous Cutting-Edge Genome Editing Techniques	23-04-18	CI
ToolGen Incorporated Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-23	CI
ToolGen Incorporated(KOSDAQ:A199800) added to S&P Global BMI Index	22-09-19	CI
MCureX Therapeutics, Inc. Signs Contract for Joint Research with Toolgen, Inc	22-06-15	CI
ToolGen Incorporated has completed an IPO in the amount of KRW 70 billion.	21-12-06	CI
ToolGen Incorporated has filed an IPO.	21-09-14	CI
ToolGen Incorporated announced that it has received KRW 10.0000004 billion in funding from Genexine, Inc.	20-12-20	CI
ToolGen Incorporated announced that it expects to receive KRW 10.0000004 billion in funding from Genexine, Inc.	20-12-10	CI
Genexine, Inc. cancelled the acquisition of ToolGen Incorporated.	19-08-19	CI
Genexine, Inc. agreed to acquire ToolGen Incorporated for approximately KRW 350 billion.	19-06-18	CI
ToolGen, Inc., Demonstrates CRISPR/Cas9 Gene Editing Improves Anti-Tumor Activity of Human Car-T Cells	18-05-17	CI
Monsanto Company and ToolGen, Inc. Announce Global Licensing Agreement on CRISPR Platform, Underscore the Benefits of Innovation for Farmers	17-08-18	CI
ToolGen, Inc. Highlights Study Results Demonstrating Utility of AAV-Compatible Cas9 System in vivo Genome Editing	17-02-22	CI
ToolGen Incorporated announced that it has received KRW 10.0223744 billion in funding	16-10-13	CI
ToolGen Incorporated announced that it expects to receive KRW 10.0223744 billion in funding	16-10-12	CI
Jong-Moon Kim acquired an additional unknown stake in ToolGen Incorporated from Seong-Hak Choi for KRW 2.7 billion.	16-02-11	CI
ToolGen, Inc. Signs License Agreement with Thermo Fisher Scientific	15-03-11	CI
ToolGen Incorporated announced that it has received KRW 2 billion in funding.	14-10-10	CI
ToolGen Incorporated announced that it expects to receive KRW 2 billion in funding.	14-10-07	CI

Chart ToolGen Incorporated

Duration

Period

More charts

Company Profile

ToolGen, Inc. is principally engaged in the development of engineered nucleases. The Companyâs main products portfolio consists of ribose nucleic acid (RNA)-guided endonucleases (RGEN) as well as deoxyribonucleic acid (DNA)-directed RGEN (dRGEN), which are applied as tools for editing genetic information in microbial, plant, animal and human cells. In addition, it is involved in the provision of genome engineering services.

Sector

Biotechnology & Medical Research

Calendar

2024-08-12 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
TOOLGEN INCORPORATED	-13.96%	351M
MODERNA, INC.	+64.92%	62.86B
IQVIA HOLDINGS INC.	-1.85%	41.38B
LONZA GROUP AG	+45.38%	40.38B
CELLTRION, INC.	-8.93%	27.64B
ICON PUBLIC LIMITED COMPANY	+13.05%	26.46B
ALNYLAM PHARMACEUTICALS, INC.	-21.96%	18.9B
BIO-TECHNE CORPORATION	+4.21%	12.67B
UNITED THERAPEUTICS CORPORATION	+25.74%	12.27B
MEDPACE HOLDINGS, INC.	+27.42%	12.07B

Other Biotechnology & Medical Research